Drug Pricing Strategies

Over the past week, the dynamics surrounding drug pricing strategies have intensified, particularly as CMS threatens to block enrollment in Medicare drug plans for Elevance Health, signaling potential shifts in access and competition within the Medicare landscape. Amidst this, a new Peterson-KFF report highlights rising prescription drug costs and the need for greater price transparency as vital issues affecting affordability, which are becoming increasingly critical for Accountable Care Organizations (ACOs) and their strategies to manage population health. These developments occur within the context of an evolving Medicare drug negotiation program, with stakeholders bracing for implications on care delivery models and financial sustainability in light of persistent cost pressures, as noted by CMS's assessment of insurers.